Pharmaron Beijing Co., Ltd. (SHE:300759)
China · Delayed Price · Currency is CNY 40.28
-1.27 (-3.06%)
Sep 11, 2026, 3:04 PM CST
Pharmaron Beijing Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 67,947 | 47,162 | 41,846 | 47,371 | 76,952 | 106,395 | |
Market Cap Growth | 23.33% | 12.70% | -11.66% | -38.44% | -27.67% | 12.84% |
Enterprise Value | 73,151 | 51,840 | 45,726 | 51,401 | 80,058 | 105,734 |
Last Close Price | 40.28 | 28.25 | 25.33 | 28.26 | 43.87 | 60.54 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 42.38 | 28.34 | 23.33 | 29.59 | 55.98 | 64.05 |
Forward PE | 27.12 | 24.72 | 26.22 | 25.72 | 35.75 | 59.23 |
PS Ratio | 4.46 | 3.35 | 3.41 | 4.11 | 7.50 | 14.29 |
PB Ratio | 3.98 | 3.00 | 2.94 | 3.58 | 7.10 | 10.33 |
P/TBV Ratio | 5.87 | 4.59 | 4.16 | 5.27 | 10.90 | 14.50 |
P/FCF Ratio | 4798.32 | 85.44 | 78.07 | - | - | - |
P/OCF Ratio | 23.45 | 14.64 | 16.24 | 17.20 | 35.91 | 51.70 |
PEG Ratio | 1.49 | 1.86 | 2.99 | 1.12 | 1.16 | 1.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.80 | 3.68 | 3.73 | 4.46 | 7.80 | 14.20 |
EV/EBITDA Ratio | 21.67 | 16.99 | 17.61 | 21.15 | 35.94 | 57.09 |
EV/EBIT Ratio | 34.65 | 25.35 | 26.60 | 30.42 | 48.04 | 73.04 |
EV/FCF Ratio | 5165.78 | 93.92 | 85.31 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.41 | 0.45 | 0.42 | 0.73 | 0.56 | 0.51 |
Debt / EBITDA Ratio | 2.06 | 2.19 | 2.16 | 3.71 | 2.59 | 2.72 |
Debt / FCF Ratio | 491.07 | 12.76 | 11.15 | - | - | - |
Net Debt / Equity Ratio | 0.26 | 0.28 | 0.21 | 0.23 | 0.30 | -0.09 |
Net Debt / EBITDA Ratio | 1.40 | 1.45 | 1.12 | 1.24 | 1.46 | -0.48 |
Net Debt / FCF Ratio | 317.89 | 8.01 | 5.44 | -26.88 | -4.04 | 25.68 |
Asset Turnover | 0.56 | 0.55 | 0.49 | 0.49 | 0.53 | 0.49 |
Inventory Turnover | 6.21 | 7.11 | 7.60 | 7.23 | 7.55 | 9.92 |
Quick Ratio | 0.68 | 0.70 | 1.44 | 2.58 | 1.31 | 2.58 |
Current Ratio | 1.02 | 0.93 | 1.80 | 2.98 | 1.67 | 2.90 |
Return on Equity (ROE) | 10.11% | 10.38% | 12.48% | 13.14% | 12.80% | 16.85% |
Return on Assets (ROA) | 4.87% | 5.01% | 4.26% | 4.50% | 5.36% | 5.97% |
Return on Invested Capital (ROIC) | 7.86% | 8.92% | 8.44% | 9.59% | 11.51% | 15.80% |
Return on Capital Employed (ROCE) | 10.40% | 10.90% | 8.70% | 7.40% | 10.10% | 9.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.52% | 3.53% | 4.29% | 3.38% | 1.79% | 1.56% |
FCF Yield | 0.02% | 1.17% | 1.28% | -0.24% | -1.05% | -0.03% |
Dividend Yield | 0.47% | 0.71% | 0.79% | 0.71% | 0.46% | 0.33% |
Payout Ratio | 31.96% | 31.92% | 30.24% | 27.78% | 29.45% | 17.14% |
Buyback Yield / Dilution | -1.96% | 0.11% | 0.11% | 0.05% | 2.40% | -1.97% |
Total Shareholder Return | -1.49% | 0.81% | 0.90% | 0.76% | 2.86% | -1.64% |